260 results match your criteria: "Cardiovascular Center Frankfurt[Affiliation]"
JACC Cardiovasc Interv
December 2024
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Electronic address:
Background: The Magenta Elevate is a 9-F, self-expanding, catheter-mounted pump delivered sheathed through a commercially available 10-F femoral introducer over the wire to the left ventricle (LV), providing temporary hemodynamic support up to an equivalent of normal cardiac output.
Objectives: The authors sought to assess the feasibility and outcomes of Elevate-supported high-risk percutaneous coronary intervention (HR-PCI) in a first-in-human study and study the hemodynamic impact of high-output support during prolonged interventional left main coronary artery (LM) occlusions.
Methods: In this study, 14 patients underwent Elevate-supported HR-PCI, with 8 patients undergoing 20 prolonged (39 ± 16 seconds) balloon occlusions of an unprotected LM.
Circulation
December 2024
Department of Pediatrics, The Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (E.M.Z.).
Background: Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009. This innovative approach was initially viewed as experimental and was reserved for highly selected patients with unusual anatomic variants. In 2016, increasing numbers of procedures began to be performed, and in several centers, it is now offered as a standard of care option alongside surgical repair.
View Article and Find Full Text PDFPostepy Kardiol Interwencyjnej
September 2024
St. John Paul II Hospital in Krakow, Stroke Thrombectomy-Capable Cardiovascular Centre, Krakow, Poland.
Clin Res Cardiol
October 2024
Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Room Rg-628, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Background: Ultrasound renal sympathetic denervation (uRDN) reduces blood pressure (BP) in the absence and presence of antihypertensive treatment at 2 months. Beyond 3 years, there is a lack of follow-up data. This study investigated the long-term safety and efficacy of uRDN.
View Article and Find Full Text PDFJACC Cardiovasc Interv
September 2024
HerzZentrum Hirslanden, Zurich, Switzerland.
Background: Transcatheter tricuspid valve intervention (TTVI) has been increasingly adopted in recent years for the treatment of patients with tricuspid regurgitation (TR). However, no dedicated risk stratification has been established for patients undergoing TTVI.
Objectives: The aim of the present study was to propose a dedicated risk score for patients affected by severe TR undergoing TTVI.
Cardiol Clin
November 2024
Cardiovascular Center Frankfurt, Frankfurt, Germany. Electronic address:
JACC Basic Transl Sci
August 2024
Department of Arrhythmia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.
In this study, we investigated the feasibility, safety, and efficiency of using a novel device system to perform percutaneous left atrial appendage occlusion concomitant with left atrial appendage electrical isolation (LAAEI) via pulsed field ablation. In the acute phase, LAAEI was successful in 10 of 10 canines. At follow-up, full endothelialization was observed in 5 of 5 (100%) cases at 6 months.
View Article and Find Full Text PDFEuroIntervention
August 2024
Swedish Heart and Vascular, Providence Swedish, Seattle, WA, USA.
Eur Heart J Cardiovasc Imaging
December 2024
HerzZentrum Hirslanden, Hirslanden Clinic, Zurich, Switzerland.
Europace
July 2024
Department of Cardiology, St Antonius Ziekenhuis Nieuwegein/AUMC Amsterdam, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands.
Postepy Kardiol Interwencyjnej
June 2024
St. John Paul II Hospital in Krakow Stroke Thrombectomy-Capable Cardiovascular Centre, Krakow, Poland.
Introduction: Acute carotid-related stroke (CRS), with its large thrombo-embolic load and large volume of affected brain tissue, poses significant management challenges. First generation (single-layer) carotid stents fail to insulate the athero-thrombotic material; thus they are often non-optimized (increasing thrombosis risk), yet their use is associated with a significant (20-30%) risk of new cerebral embolism.
Aim: To evaluate, in a multi-center multi-specialty investigator-initiated study, outcomes of the MicroNET-covered (cell area ≈ 0.
JACC Cardiovasc Interv
June 2024
Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada. Electronic address:
Eur J Heart Fail
April 2024
Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
JACC Cardiovasc Interv
April 2024
HerzZentrum Hirslanden, Zurich, Switzerland.
Int J Cardiol
June 2024
HerzZentrum Hirslanden, Zurich, Switzerland.
Aims: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter.
View Article and Find Full Text PDFClin Radiol
April 2024
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Gates Vascular Institute at Kaleida Health, Buffalo, NY, USA; Canon Stroke and Vascular Research Center, University at Buffalo, Buffalo, NY, USA; Jacobs Institute, Buffalo, NY, USA.
JACC Cardiovasc Interv
November 2023
Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Department of Cardiology, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain. Electronic address:
Eur J Heart Fail
December 2023
HerzZentrum Hirslanden, Zurich, Switzerland.
Sci Bull (Beijing)
August 2023
CardioVascular Center Frankfurt, Frankfurt 60389, Germany. Electronic address:
ESC Heart Fail
August 2023
Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes and Saarland University, Homburg, Germany.
Struct Heart
August 2022
Cardiac Success Ltd, Yokneam, Israel.
Struct Heart
October 2022
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: Endovascular baroreflex amplification with the MobiusHD, a self-expanding stent-like device that is implanted in the internal carotid artery, was designed to reduce the sympathetic overactivity that contributes to progressive heart failure with reduced ejection fraction.
Methods: Symptomatic patients (New York Heart Association class III) with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) despite guideline directed medical therapy and n-terminal pro-B type natriuretic peptide (NT-proBNP) levels ≥400 pg/mL in whom carotid ultrasound and computed tomographic angiography demonstrated absence of carotid plaque were enrolled. Baseline and follow-up measures included 6-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ OSS), and repeat biomarkers and transthoracic echocardiography.
Struct Heart
May 2023
Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, Oregon, USA.
Background: Patients with dialysis-dependent end-stage renal disease (ESRD) taking midodrine may be at high risk for poor outcomes following transcatheter aortic valve replacement (TAVR). We evaluated dialysis-dependent ESRD patients taking midodrine.
Methods: We conducted a retrospective analysis of non-clinical trial TAVR patients from February 2012 to December 2020 from 11 facilities in a Western US health system.
Int J Environ Res Public Health
April 2023
Cardiovascular Center Frankfurt, 60389 Frankfurt, Germany.
Clinical and economic burdens exist within the coronary artery disease (CAD) care pathway despite advances in diagnosis and treatment and the increasing utilization of percutaneous coronary intervention (PCI). However, research presenting a comprehensive assessment of the challenges across this pathway is scarce. This contemporary review identifies relevant studies related to inefficiencies in the diagnosis, treatment, and management of CAD, including clinician, patient, and economic burdens.
View Article and Find Full Text PDFEur J Heart Fail
June 2023
Cardiology Department, Rabin Medical Center, Tel-Aviv University, Petach Tikva, Israel.
Aims: In heart failure (HF), implantable haemodynamic monitoring devices have been shown to optimize therapy, anticipating clinical decompensation and preventing hospitalization. Direct left-sided haemodynamic sensors offer theoretical benefits beyond pulmonary artery pressure monitoring systems. We evaluated the safety, usability, and performance of a novel left atrial pressure (LAP) monitoring system in HF patients.
View Article and Find Full Text PDF